Safety and Immunogenicity Study of the Hepatitis B Virus (HBV) Vaccine, HEPLISAV Compared to Engerix-B Vaccine

NCT01005407 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

2452

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy

Interventions

BIOLOGICAL: HEPLISAV and/or Placebo
BIOLOGICAL: Engerix-B

Sponsor

Dynavax Technologies Corporation